The drug, MBP134, developed by Mapp Biopharmaceutical, will be used in clinical trials and for compassionate treatment.

The United States has supplied doses of an experimental Ebola treatment to the Democratic Republic of Congo to support efforts against the growing Bundibugyo Ebola outbreak.

The drug, MBP134, developed by Mapp Biopharmaceutical, will be used in clinical trials and for compassionate treatment.

The outbreak has infected more than 1,000 people and caused over 250 deaths in Congo, with additional cases reported in Uganda.

Health officials say trials of MBP134 and two antiviral drugs from Gilead Sciences are expected to begin in the coming weeks.

The studies will assess their effectiveness against the Bundibugyo strain, which currently has no approved vaccine or treatment.

According to the World Health Organization, vaccine development is also underway, although human trials are expected to take longer to launch.

Health experts warn that conducting trials in eastern Congo will be challenging due to ongoing conflict, limited healthcare infrastructure, and difficulties in tracking infections.

However, they say the research is critical to finding effective treatments and controlling the outbreak.

Join us on our WhatsApp Platform @KOIKIMEDIA NEWS YOUR PAGE

koikimedia Bringing the World 🌎 Closer to Your Doorstep